1-benzyl-4-(N-tert-butoxycarbonyl-N-isopropylamino)piperidine 在
钯氮气 、 氢气 、 乙醇 作用下,
以
乙醇 为溶剂,
反应 24.5h,
以to afford 57.0 g of the title intermediate as a white solid (>99% yield)的产率得到4-(N-tert-butoxycarbonyl-N-isopropylamino)piperidine
参考文献:
名称:
Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds
[EN] 1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS 1,4 DI SUBSTITUÉS PYROLIDINE-3-YL-AMINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:PROSIDION LTD
公开号:WO2012066077A1
公开(公告)日:2012-05-24
Therapeutic compounds are disclosed having the general formula (1) that are useful for the treatment of metabolic disorders, including type II diabetes.The compounds have activity as agonists of GPR1 19. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
[EN] 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PYROLIDIN-3-YL-AMINE 1,4 DISUBSTITUÉE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:PROSIDION LTD
公开号:WO2013026587A1
公开(公告)日:2013-02-28
Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound
申请人:Wilson D. Richard
公开号:US20050113413A1
公开(公告)日:2005-05-26
This invention provides naphthalene-1,5-disulfonic acid salts of 4-N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine, which salts are useful as muscarinic receptor antagonists. This invention is also directed to pharmaceutical compositions comprising these salt forms, methods of using these salt forms for treating medical conditions mediated by muscarinic receptors; and processes for preparing these salt forms.